Overview of Breathing Muscle Weakness in Neuromuscular Disease (NMD)

Title: Overview of Breathing Muscle Weakness in Neuromuscular Disease (NMD)

Date: Thursday, September 25, 2025

Time: 1 PM CST / 2 PM EST

Speaker:
Andrea Klein

Webinar Overview:
An introduction to the concepts of breathing and coughing muscle weakness, this presentation highlights the importance of medical self-advocacy to ensure positive outcomes. Topics include the role of muscles in breathing, the relevance of blood gases, the evaluation process, appropriate interventions, and more.

Speaker Biography

Andrea Klein

Founder & President – Breathe with MD, Inc.

Having earned a Bachelor of Science in English-Journalism with a concentration in Public Relations from Tennessee Technological University in 1996, Andrea has worked in the healthcare IT field for nearly 25 years. She is co-author of a chapter in the textbook “Non-Invasive Ventilation and Weaning: Principles and Practice, Second Edition,” published in 2018. She served as Ms. Wheelchair Tennessee 2017 and received the Lifetime Achievement Award at the Ms. Wheelchair America 2018 competition.

She founded Breathe with MD, Inc. in memory of her middle sister, Cheryl Lewis, who died because of inappropriate care for neuromuscular respiratory failure. Andrea has a passion for educating others about breathing muscle weakness and the importance of medical self-advocacy. She developed and implemented Breathe with MD’s “Breathing Muscle Weakness 101” online course, which has enrolled nearly 250 participants in the last two years.

Andrea lives with Intermediate Collagen 6 Congenital Muscular Dystrophy and has used non-invasive ventilation since 2013 and mechanical cough assistance since 2014.

Genzyme Pompe Program Update—April 2008

We would like to take this opportunity to provide an important update related to Myozyme (alglucosidase alfa) manufacturing in the United States.  The FDA has informed Genzyme of its decision on the application for the larger scale manufacturing process to...

January 2008 US Myozyme Supply Update

In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in order to ensure uninterrupted treatment for as many patients as possible.  Since April, both the patient and physician communities have...

Genzyme Study of Myozyme® for Late-Onset Pompe Patients

CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme® (alglucosidase alfa) met its co-primary efficacy endpoints.  The study was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and...

MTAP Fact Sheet June 2007

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP...

Genzyme Pompe Program Update—June 2007

Genzyme would like to take this opportunity to provide a brief update to the Pompe patient community regarding the US supply of Myozyme® (alglucosidase alfa).  As planned, Genzyme submitted the necessary documentation to the FDA this month for the licensure of the...

MTAP Fact Sheet May 2007

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP...

Genzyme Pompe Program Update—April 2007

As many of you are aware, a standard part of the biologics drug development process is to incrementally scale-up manufacturing capacity as demand for the product increases. During the development of Myozyme®, Genzyme began the manufacturing process using a smaller...

Letter From IPA and Genzyme Concerning LOTS

Dear IPA members, Pompe patients, family members and GSD-net participants, The IPA board received several questions concerning participation in the LOTS trial. As there are certain restrictions to the market approval of Myozyme we asked Genzyme to make a written...